Zimmer Biomet Holdings, Inc. filings document a public medical technology company with common stock listed under ZBH and several registered notes listed on the New York Stock Exchange. Recent 8-K reports cover quarterly and annual operating results, updated financial guidance, executive officer departures and interim finance leadership, debt securities, and completed acquisition activity.
The company's proxy and event filings disclose board and executive compensation matters, governance votes, Section 12(b) securities, material agreements, senior unsecured debt obligations, and exhibits tied to earnings releases. These records frame Zimmer Biomet's capital structure, leadership changes, shareholder governance and financial reporting for its orthopedic and musculoskeletal technology business.
Shapiro Louis reported acquisition or exercise transactions in this Form 4 filing.
ZIMMER BIOMET HOLDINGS, INC. director Louis Shapiro reported receiving a grant of phantom stock units as part of his non-employee director compensation. He was awarded 158.684 phantom stock units tied to company common stock on a 1-for-1 basis, bringing his total phantom stock holdings to 3,703.100 units. These units were accrued under the company’s Deferred Compensation Plan for Non-Employee Directors and will be settled in shares of Zimmer Biomet common stock within sixty days after he ceases serving as a director.
Zimmer Biomet Holdings, Inc. entered into two new unsecured revolving credit agreements to support general corporate purposes. The company established a five-year revolving facility of $1.5 billion maturing on June 26, 2031, with two optional one-year extensions, and an uncommitted incremental feature of up to $750 million.
It also put in place a separate 364-day revolving facility of $1.25 billion maturing on June 25, 2027. Both agreements bear floating interest based on adjusted Term SOFR or an alternate base rate plus a margin tied to the company’s senior unsecured long-term debt rating and require a consolidated indebtedness to consolidated EBITDA ratio not exceeding 4.5 to 1.0, with a step-up to 5.0 to 1.0 for qualified material acquisitions.
At the same time, Zimmer Biomet terminated its prior 2025 five-year and 364-day credit agreements, both of which had no principal outstanding. The company paid approximately $0.4 million of fees due under the prior five-year agreement using cash on hand, and existing letters of credit were transitioned to the new five-year facility.
ZBH submitted a Form 144 notice reporting proposed sales of Common Stock by a selling holder. The filing lists two recent sale transactions: 31,252 shares sold on 05/12/2026 for $2,608,859.38 and 5,373 shares sold on 05/19/2026 for $464,120.14.
The filing also records restricted stock vesting events of 2,091 shares on 07/01/2023 and 2,469 shares on 02/25/2024, and shows a broker/location entry referencing Fidelity Brokerage Services LLC with a date of 06/24/2026.
Noor Jehanzeb reported acquisition or exercise transactions in this Form 4 filing.
ZIMMER BIOMET HOLDINGS, INC. officer Noor Jehanzeb received a grant of 1,857 Restricted Stock Units, each representing a right to one share of common stock. These RSUs vest over three years in equal one-third installments starting on June 1, 2027. After this award, Jehanzeb holds 1,857 RSUs directly.
ZIMMER BIOMET HOLDINGS, INC. executive Yi Sang, Group President, Asia Pacific, reported selling a total of 5,000 shares of Common Stock in open-market transactions on May 29, 2026 at prices around $82.65 per share. After these sales, he continues to hold a substantial direct position of over 27,000 shares.
Fidelity Brokerage Services LLC submitted a Form 144 notice to sell 5,000 shares of Common Stock (aggregate value $413,216.42) for issuer with CUSIP 193462482 on 05/29/2026.
The filing lists prior acquisitions of Common Stock by the reporting account through restricted stock vesting and ESPP purchases on 03/06/2024 (1,308 shares), 06/28/2024 (136 shares), 12/31/2024 (80 shares) and 02/18/2025 (3,476 shares).
Zimmer Biomet Holdings, Inc. reported the results of its annual shareholder meeting held on May 22, 2026. Shareholders elected ten directors to one-year terms ending at the 2027 annual meeting, with each nominee receiving over 160 million votes in favor and substantial broker non-votes recorded.
Shareholders also ratified the Audit Committee’s appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for 2026, with 172,738,361 votes for and relatively few votes against or abstaining. On an advisory basis, they approved named executive officer compensation, with 160,066,066 votes for and 8,386,847 against. A shareholder proposal seeking an independent board chair was rejected, drawing 31,288,886 votes for and 137,043,058 against.
Farrell Michael J. reported acquisition or exercise transactions in this Form 4 filing.
Zimmer Biomet Holdings director Michael J. Farrell received new equity-based awards as part of his board compensation. On May 22, 2026, he was granted 1,517.274 Restricted Stock Units tied to common stock, bringing his total Restricted Stock Units to 13,757.
On the same date, he also received 875.350 Phantom Stock Units under the company’s Deferred Compensation Plan for Non-Employee Directors, increasing his phantom unit balance to 19,173.940. These units are generally settled in shares of common stock after his board service ends and are subject to mandatory deferral and dividend reinvestment features.
BERNARD BETSY J reported acquisition or exercise transactions in this Form 4 filing.
ZIMMER BIOMET HOLDINGS, INC. director Betsy J. Bernard received equity-based compensation rather than trading shares in the market. She was granted 1,517.274 Restricted Stock Units and 875.350 Phantom Stock Units, each representing 1-for-1 rights to common stock.
The Restricted Stock Units are immediately 100% vested but must be deferred until the later of her board departure or three years after grant. The Phantom Stock Units, accrued under the Deferred Compensation Plan for Non-Employee Directors, will be settled in common shares within sixty days after her service as a director ends. Following these awards, her reported holdings rose to 24,506 Restricted Stock Units and 21,581.562 Phantom Stock Units.
Zimmer Biomet director Maria Teresa Hilado received new equity awards as part of her board compensation. On May 22, 2026, she was granted 1,517.274 Restricted Stock Units tied to common stock, bringing her total Restricted Stock Units holdings to 9,098. These units are immediately 100% vested but are subject to mandatory deferral until the later of her termination of service as a director or three years after the grant date.
She was also granted 875.350 Phantom Stock Units under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors, increasing her phantom stock balance to 12,594.369 units. The phantom units convert 1-for-1 into company common stock and are to be settled in shares within sixty days after she ceases serving as a director. The phantom balance includes 34.300 units accrued on April 30, 2026 through a dividend reinvestment provision, and some Restricted Stock Units granted in prior years remain subject to different mandatory deferral periods.